Predicting Heart Disease: New Study Validates PREVENT and SCORE2 Risk Scores Globally
For decades, physicians have relied on cardiovascular risk scores to determine who needs aggressive intervention—like statins or blood pressure medication—to prevent heart attacks and strokes. However, different regions have historically used different tools, leading to questions about whether a score developed in the United States is as accurate as one developed in Europe.
A comprehensive new study published in Nature Medicine provides a definitive answer. By analyzing data from 44 observational studies and 18 randomized trials, researchers found that the two leading risk assessment tools—the PREVENT score (used in the U.S.) and the SCORE2 score (used in Europe)—perform similarly and remain effective across diverse geographical regions.
Understanding Cardiovascular Risk Scores
A cardiovascular risk score isn’t a diagnosis; it’s a probability. It uses a variety of patient data—such as age, cholesterol levels, blood pressure and smoking status—to estimate the likelihood that a person will experience a major cardiovascular event, such as a myocardial infarction (heart attack) or stroke, over the next ten years.
The goal is to move away from a “one size fits all” approach. Instead of treating everyone with high cholesterol the same way, doctors use these scores to identify “high-risk” individuals who will benefit most from medication, while avoiding over-treatment in “low-risk” individuals.
PREVENT vs. SCORE2: What’s the Difference?
While both tools aim to predict the same outcomes, they were developed using different populations and clinical priorities:
- PREVENT: The newer standard in the United States, designed to incorporate a broader range of health markers to better predict cardiovascular disease and kidney failure.
- SCORE2: The established European standard, calibrated specifically for different European regions to account for varying baseline risks across the continent.
Until recently, there was uncertainty about whether these tools were interchangeable or if one was significantly more accurate when applied to global populations. The Nature Medicine validation study confirms that both scores provide reliable performance, regardless of the geographical region of the patient.
Why This Validation Matters for Patients
The fact that PREVENT and SCORE2 show similar performance is a win for global health equity. It suggests that the fundamental biological drivers of heart disease are being captured consistently by both tools.
For the patient, this means more confidence in the clinical guidance they receive. Whether a physician is using the U.S.-based PREVENT model or the European SCORE2 model, the resulting risk category is likely to be accurate. This consistency allows for more standardized care and ensures that life-saving preventative treatments are administered to the right people at the right time.
Key Takeaways: Cardiovascular Risk Validation
- Broad Evidence: The study utilized a massive dataset, including 44 observational studies and 18 randomized trials.
- Comparable Accuracy: There is no significant performance gap between the PREVENT and SCORE2 scores.
- Global Reliability: Both tools performed well across various geographical regions, proving their utility on a multinational scale.
- Clinical Impact: This validation reinforces the use of these scores in guiding preventative therapies for heart disease.
Frequently Asked Questions
Do I need to worry if my risk score is “borderline”?
A borderline score is often a catalyst for a deeper conversation with your doctor. It may lead to additional screenings, such as a Calcium Score (CT scan of the heart), or a more aggressive focus on lifestyle modifications like diet and exercise before starting medication.
Can a risk score change over time?
Yes. Risk scores are snapshots in time. If you quit smoking, lower your LDL cholesterol, or successfully manage your hypertension, your 10-year risk score will decrease. Regular re-evaluation is key to tracking the success of your preventative health plan.
Which score is “better”?
According to the recent findings in Nature Medicine, neither is definitively “better” than the other; both show generally good performance and similar accuracy across different populations.
The Path Forward in Heart Health
The validation of PREVENT and SCORE2 marks a step toward a more unified global approach to cardiovascular prevention. As we move further into the era of personalized medicine, the next frontier will likely involve integrating genetic markers and AI-driven data into these scores to make them even more precise. For now, clinicians can feel confident that these established tools are providing a reliable roadmap for protecting heart health worldwide.